BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 61 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $220,000 | -62.7% | 887,228 | -22.2% | 0.00% | – |
| Q2 2022 | $590,000 | -77.7% | 1,140,870 | -11.5% | 0.00% | – |
| Q1 2022 | $2,642,000 | -51.7% | 1,288,991 | -1.6% | 0.00% | – |
| Q4 2021 | $5,465,000 | +8.1% | 1,310,490 | +141.0% | 0.00% | – |
| Q3 2021 | $5,057,000 | -31.4% | 543,839 | +32.9% | 0.00% | – |
| Q2 2021 | $7,368,000 | – | 409,098 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cypress Point Wealth Management, LLC | 1,887,509 | $977,000 | 1.71% |
| Naviter Wealth, LLC | 1,572,803 | $814,000 | 0.33% |
| ARMISTICE CAPITAL, LLC | 4,342,561 | $2,248,000 | 0.04% |
| INVERNESS COUNSEL LLC /NY/ | 1,210,537 | $627,000 | 0.04% |
| Ground Swell Capital, LLC | 13,616 | $7,000 | 0.01% |
| BALDWIN BROTHERS LLC/MA | 40,604 | $21,000 | 0.00% |
| Allegheny Financial Group LTD | 11,595 | $6,000 | 0.00% |
| Ergoteles LLC | 145,500 | $75,000 | 0.00% |
| Renaissance Technologies | 1,215,800 | $629,000 | 0.00% |
| Carmichael Hill & Associates, Inc. | 1,500 | $1,000 | 0.00% |